Researchers have developed a novel positron emission tomography (PET) tracer targeting nectin-4, allowing same-day immuno-PET imaging of triple-negative breast cancer and urothelial bladder carcinoma. This technology enhances rapid detection and management of aggressive cancers characterized by high nectin-4 expression, potentially transforming clinical workflows through more timely and precise molecular imaging.